OBJECTIVE: This study examined the effect of hormone therapy (HT) on the plasma concentration of remnant lipoprotein cholesterol (RLP-C) and high-density lipoprotein (HDL) subpopulations and the contribution of HT-related changes in these lipoproteins to the progression of coronary heart disease (CHD) in postmenopausal women. METHODS:Study participants were 256 women who completed the Estrogen Replacement and Atherosclerosis (ERA) trial, aplacebo-controlled, randomized trial that examined the effects of 3.2 years of conjugated equine estrogen (CEE, 0.625 mg/day) or CEE (0.625 mg/day) plus medroxyprogesterone acetate (MPA, 2.5mg/day) on postmenopausal women with established coronary atherosclerosis. Quantitative coronary angiography and plasma RLP-C and HDL subpopulations were assessed at baseline and at follow-up. RESULTS: Relative to placebo, both CEE and CEE+MPA caused a significant reduction in plasma RLP-C concentrations and a significant increase in alpha1 and alpha2 HDL subpopulations. However, in the HT-treated subjects, faster progression of coronary atherosclerosis was observed in women who experienced the greatest reductions in RLP-C and in prebeta1 HDL subpopulations. CONCLUSIONS: Our data suggest that individual variability in RLP-C and HDL subpopulation response to HT is a predictor of CHD progression. Lipoprotein response to HT may be an indirect marker of susceptibility to other harmful effect of HT in postmenopausal women with established CHD or an indication of formation of dysfunctional lipoproteins.
RCT Entities:
OBJECTIVE: This study examined the effect of hormone therapy (HT) on the plasma concentration of remnant lipoprotein cholesterol (RLP-C) and high-density lipoprotein (HDL) subpopulations and the contribution of HT-related changes in these lipoproteins to the progression of coronary heart disease (CHD) in postmenopausal women. METHODS: Study participants were 256 women who completed the Estrogen Replacement and Atherosclerosis (ERA) trial, a placebo-controlled, randomized trial that examined the effects of 3.2 years of conjugated equine estrogen (CEE, 0.625 mg/day) or CEE (0.625 mg/day) plus medroxyprogesterone acetate (MPA, 2.5mg/day) on postmenopausal women with established coronary atherosclerosis. Quantitative coronary angiography and plasma RLP-C and HDL subpopulations were assessed at baseline and at follow-up. RESULTS: Relative to placebo, both CEE and CEE+MPA caused a significant reduction in plasma RLP-C concentrations and a significant increase in alpha1 and alpha2 HDL subpopulations. However, in the HT-treated subjects, faster progression of coronary atherosclerosis was observed in women who experienced the greatest reductions in RLP-C and in prebeta1 HDL subpopulations. CONCLUSIONS: Our data suggest that individual variability in RLP-C and HDL subpopulation response to HT is a predictor of CHD progression. Lipoprotein response to HT may be an indirect marker of susceptibility to other harmful effect of HT in postmenopausal women with established CHD or an indication of formation of dysfunctional lipoproteins.
Authors: Pamela Ouyang; Jean-Claude Tardif; David M Herrington; Kerry J Stewart; Paul D Thompson; Mary N Walsh; Susan K Bennett; Alan W Heldman; Matthew A Tayback; Nae-Yuh Wang Journal: Atherosclerosis Date: 2006-01-24 Impact factor: 5.162
Authors: Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Timothy J Wilt; Hanna E Bloomfield; Roderick MacDonald; David Nelson; Indulis Rutks; Michael Ho; Gregory Larsen; Anthony McCall; Sandra Pineros; Anne Sales Journal: Arch Intern Med Date: 2004-07-12
Authors: Stefania Lamon-Fava; Borbala Posfai; Bela F Asztalos; Katalin V Horvath; Gerard E Dallal; Ernst J Schaefer Journal: Metabolism Date: 2003-10 Impact factor: 8.694
Authors: Vasilios G Athyros; Dimitri P Mikhailidis; Athanasios A Papageorgiou; Athanasios N Symeonidis; Bodosakis R Mercouris; Anthimos Pehlivanidis; Vasilios I Bouloukos; Moses Elisaf Journal: Curr Med Res Opin Date: 2004-05 Impact factor: 2.580
Authors: Bela F Asztalos; Marcelo Batista; Katalin V Horvath; Caitlin E Cox; Gerard E Dallal; Josh S Morse; Greg B Brown; Ernst J Schaefer Journal: Arterioscler Thromb Vasc Biol Date: 2003-03-13 Impact factor: 8.311
Authors: Stefania Lamon-Fava; David M Herrington; Katalin V Horvath; Ernst J Schaefer; Bela F Asztalos Journal: Metabolism Date: 2010-06-26 Impact factor: 8.694
Authors: Alvaro Pulchinelli; Ana Maria Massad Costa; Cristina V de Carvalho; Naiara Correa Nogueira de Souza; Mauro A Haidar; Adagmar Andriolo; Ismael D C Guerreiro da Silva Journal: Lipids Health Dis Date: 2011-11-02 Impact factor: 3.876
Authors: Stefania Lamon-Fava; Bela F Asztalos; Timothy D Howard; David M Reboussin; Katalin V Horvath; Ernst J Schaefer; David M Herrington Journal: Clin Endocrinol (Oxf) Date: 2009-05-29 Impact factor: 3.478
Authors: Tomas Vaisar; Jennifer L Gordon; Jake Wimberger; Jay W Heinecke; Alan L Hinderliter; David R Rubinow; Susan S Girdler; Katya B Rubinow Journal: J Clin Lipidol Date: 2020-11-24 Impact factor: 4.766